FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3190776070> ?p ?o ?g. }

• W3190776070 endingPage "4363" @default.
• W3190776070 startingPage "4360" @default.
• W3190776070 abstract "Takotsubo syndrome (TTS) is a stress-induced acute cardiac syndrome characterized by transient, reversible left ventricular (LV) systolic dysfunction in the absence of coronary artery obstruction.1 TTS represents approximately 1–3% of all and 5–6% of female patients presenting with the suspected acute coronary syndrome.2, 3 About 60% of patients with TTS present with LV ejection fraction (LVEF) ≤40%, and up to 20% experience severe complications in the acute phase, including acute heart failure and cardiogenic shock.4, 5 The in-hospital mortality varies between 1% and 5%, similar to patients with acute myocardial infarction due to obstructive coronary artery disease.6 The mechanisms underlying the onset of TTS are not fully established; therefore, therapeutic management remains merely empirical. Circulating levels of plasma catecholamines can cause acute myocardial stunning in TTS; however, the exogenous use of catecholamines (i.e. adrenaline, dobutamine, and dopamine), particularly in patients with LV outflow tract obstruction, is contraindicated.7 Thus, a better therapeutic option seems to be a non-catecholamine inotrope, the calcium-sensitizing inodilator levosimendan, which is the inotrope of choice in acutely decompensated severe congestive heart failure where conventional therapy is insufficient and conditions where inotropic support is considered appropriate.8 In this context, TTS may represent an ideal target for this non-catecholamine inotrope; however, this statement also relies on expert opinion.9 Herein, we performed a pooled analysis of studies evaluating the efficacy and safety of levosimendan in TTS. Two authors (L. S. and M. J. J.) searched the electronic resources (MEDLINE, MEDLINE In-Process, Embase, Cochrane Library for clinical trials, PubMed, Web of Science, and Scopus) from database inception to 15 November 2020. Subsequently, the relevant article bibliographies and searched articles were analysed and reviewed for relevance to title and abstract. The key search words were ‘levosimendan’ AND ‘takotsubo cardiomyopathy’ OR ‘stress cardiomyopathy’ OR ‘apical ballooning syndrome’ OR ‘broken heart syndrome’. All results are presented as mean difference (MD) or odds ratio with their 95% confidence interval (CI). When the continuous outcome was reported in a study as median, range, and inter-quartile range, we estimated means and standard deviations using the formula described by Hozo et al. P < 0.05 two-tailed statistical testing was considered statistically significant. The analyses were performed using RevMan5.4 (The Cochrane Collaboration, Oxford, Copenhagen, Denmark). The full list of publications included in the pooled analysis is presented in the Supporting Information. Eight studies including 272 patients were selected for quantitative analysis. All studies reported the use of levosimendan in TTS patients who required inotropic support (Supporting Information, Table S1), compared to standard treatment: one randomized double-blind study, three observational studies (including one conference paper), and four cases studies. In the pooled analysis (Table 1), the baseline characteristics were comparable between the levosimendan and control groups. At admission, NT-proBNP, serum creatinine, and LV ejection fraction were lower on levosimendan therapy (P = 0.006, P < 0.001, and P = 0.002, respectively). At discharge or after 30 days, LVEF was higher in the levosimendan group compared to the control group (MD = 1.4; 95% CI: 0.32, 2.48; P = 0.01), whereas NT-proBNP was lower on levosimendan therapy (MD = −98.30; 95% CI: −122.21, −74.39; P < 0.001). The hospital stay duration (MD = −4.90; 95% CI: −5.90, −3.90; P < 0.001), time to recover to the baseline troponin values (MD = −3.10; 95% CI: −4.31, −1.89; P < 0.001), and time to rise in LVED above 50% (MD = −2.50; 95% CI: −4.01, −0.99; P = 0.001) were shorter in the levosimendan group compared to the control group. There was a trend towards lower mortality in the levosimendan group (OR 0.29; 95% CI 0.07, 1.12; P = 0.07). There were 13/135 adverse events related to levosimendan during hospitalizations (9.8%). Our pooled analysis demonstrates that the use of levosimendan might be associated with a reduced length of hospital stay and a rapid recovery time in patients with TTS who required inotropic support, although the bias due to the differences in baseline characteristics cannot be excluded. The major limitation of this analysis is the lack of statistical power to detect differences in mortality. Although the lack of early LVEF recovery is an independent predictor of adverse long-term outcomes, including mortality,10 the significant difference in LVEF remains clinically less relevant than the mortality endpoint. Moreover, the length of hospital stay and time to recover to the baseline troponin values were assessed based on 17 vs. 25 patients only, making the results hypothesis generating rather than ultimately demonstrating the benefits of levosimendan in TTS. Finally, the low rate of adverse effects such as pulmonary oedema and dyspnoea should also be interpreted with caution, considering that all patients were initially in NYHA Class IV. Altogether, further randomized studies are warranted to confirm these preliminary results. This study was supported by the ERC Research NET and Polish Society of Disaster Medicine. Table S1. Main characteristics of the studies reporting levosimendan use in patients with takotsubo syndrome who required inotropic support. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W3190776070 created "2021-08-16" @default.
• W3190776070 creator A5007660537 @default.
• W3190776070 creator A5021903478 @default.
• W3190776070 creator A5022117993 @default.
• W3190776070 creator A5041356090 @default.
• W3190776070 creator A5068721693 @default.
• W3190776070 creator A5071808522 @default.
• W3190776070 date "2021-08-02" @default.
• W3190776070 modified "2023-10-01" @default.
• W3190776070 title "Levosimendan improves the acute course of takotsubo syndrome: a pooled analysis" @default.
• W3190776070 cites W1532644443 @default.
• W3190776070 cites W2004582234 @default.
• W3190776070 cites W2170844292 @default.
• W3190776070 cites W2803506515 @default.
• W3190776070 cites W2805683701 @default.
• W3190776070 cites W2805755253 @default.
• W3190776070 cites W2905130449 @default.
• W3190776070 cites W2986706036 @default.
• W3190776070 cites W2990269274 @default.
• W3190776070 cites W3047267110 @default.
• W3190776070 doi "https://doi.org/10.1002/ehf2.13486" @default.
• W3190776070 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8497347" @default.
• W3190776070 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34342162" @default.
• W3190776070 hasPublicationYear "2021" @default.
• W3190776070 type Work @default.
• W3190776070 sameAs 3190776070 @default.
• W3190776070 citedByCount "8" @default.
• W3190776070 countsByYear W31907760702022 @default.
• W3190776070 countsByYear W31907760702023 @default.
• W3190776070 crossrefType "journal-article" @default.
• W3190776070 hasAuthorship W3190776070A5007660537 @default.
• W3190776070 hasAuthorship W3190776070A5021903478 @default.
• W3190776070 hasAuthorship W3190776070A5022117993 @default.
• W3190776070 hasAuthorship W3190776070A5041356090 @default.
• W3190776070 hasAuthorship W3190776070A5068721693 @default.
• W3190776070 hasAuthorship W3190776070A5071808522 @default.
• W3190776070 hasBestOaLocation W31907760701 @default.
• W3190776070 hasConcept C126322002 @default.
• W3190776070 hasConcept C151730666 @default.
• W3190776070 hasConcept C155710745 @default.
• W3190776070 hasConcept C164705383 @default.
• W3190776070 hasConcept C178853913 @default.
• W3190776070 hasConcept C2775992611 @default.
• W3190776070 hasConcept C2776850375 @default.
• W3190776070 hasConcept C2777335384 @default.
• W3190776070 hasConcept C2778198053 @default.
• W3190776070 hasConcept C2778213512 @default.
• W3190776070 hasConcept C2779295919 @default.
• W3190776070 hasConcept C2779343474 @default.
• W3190776070 hasConcept C2781185063 @default.
• W3190776070 hasConcept C500558357 @default.
• W3190776070 hasConcept C541997718 @default.
• W3190776070 hasConcept C71924100 @default.
• W3190776070 hasConcept C78085059 @default.
• W3190776070 hasConcept C86803240 @default.
• W3190776070 hasConceptScore W3190776070C126322002 @default.
• W3190776070 hasConceptScore W3190776070C151730666 @default.
• W3190776070 hasConceptScore W3190776070C155710745 @default.
• W3190776070 hasConceptScore W3190776070C164705383 @default.
• W3190776070 hasConceptScore W3190776070C178853913 @default.
• W3190776070 hasConceptScore W3190776070C2775992611 @default.
• W3190776070 hasConceptScore W3190776070C2776850375 @default.
• W3190776070 hasConceptScore W3190776070C2777335384 @default.
• W3190776070 hasConceptScore W3190776070C2778198053 @default.
• W3190776070 hasConceptScore W3190776070C2778213512 @default.
• W3190776070 hasConceptScore W3190776070C2779295919 @default.
• W3190776070 hasConceptScore W3190776070C2779343474 @default.
• W3190776070 hasConceptScore W3190776070C2781185063 @default.
• W3190776070 hasConceptScore W3190776070C500558357 @default.
• W3190776070 hasConceptScore W3190776070C541997718 @default.
• W3190776070 hasConceptScore W3190776070C71924100 @default.
• W3190776070 hasConceptScore W3190776070C78085059 @default.
• W3190776070 hasConceptScore W3190776070C86803240 @default.
• W3190776070 hasIssue "5" @default.
• W3190776070 hasLocation W31907760701 @default.
• W3190776070 hasLocation W31907760702 @default.
• W3190776070 hasLocation W31907760703 @default.
• W3190776070 hasLocation W31907760704 @default.
• W3190776070 hasOpenAccess W3190776070 @default.
• W3190776070 hasPrimaryLocation W31907760701 @default.
• W3190776070 hasRelatedWork W2068616973 @default.
• W3190776070 hasRelatedWork W2133889186 @default.
• W3190776070 hasRelatedWork W2135619337 @default.
• W3190776070 hasRelatedWork W2390968953 @default.
• W3190776070 hasRelatedWork W2789560201 @default.
• W3190776070 hasRelatedWork W3094089155 @default.
• W3190776070 hasRelatedWork W3166211984 @default.
• W3190776070 hasRelatedWork W3203709221 @default.
• W3190776070 hasRelatedWork W4200109519 @default.
• W3190776070 hasRelatedWork W4622096 @default.
• W3190776070 hasVolume "8" @default.
• W3190776070 isParatext "false" @default.
• W3190776070 isRetracted "false" @default.
• W3190776070 magId "3190776070" @default.
• W3190776070 workType "article" @default.